Cargando…
Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report
RATIONALE: A hormone-active metastatic Hürthle cell thyroid carcinoma (HCTC) and Graves disease (GD) present a therapeutic challenge and is rarely reported. PATIENT CONCERNS: We present a 64-year-old male patient, who had dyspnea and left hip pain lasting 4 months. He had clinical signs of hyperthyr...
Autores principales: | Besic, Nikola, Vidergar-Kralj, Barbara, Zaletel, Katja, Grasic-Kuhar, Cvetka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238273/ https://www.ncbi.nlm.nih.gov/pubmed/34160415 http://dx.doi.org/10.1097/MD.0000000000026384 |
Ejemplares similares
-
Treatment and outcome of patients with Graves’ disease and metastatic differentiated thyroid cancer
por: Besic, Nikola, et al.
Publicado: (2023) -
Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience
por: Besic, Nikola, et al.
Publicado: (2016) -
Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma
por: Krhin, Blaz, et al.
Publicado: (2016) -
Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma
por: Zagar, Ivana, et al.
Publicado: (2012) -
Thyroid hormone resistance syndrome with P453T mutation in thyroid hormone receptor β gene: A pedigree report
por: Yusufu, Ayiguli, et al.
Publicado: (2020)